William B Tabayoyong1, Ashish M Kamat1, Michael A O'Donnell2, James M McKiernan3, Mohamed D Ray-Zack4, Joan Palou5, Maurizio Brausi6, Peter C Black7, Stephen B Williams8. 1. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Urology, The University of Iowa, Iowa City, IA, USA. 3. Department of Urology, Columbia University Medical Center, New York, NY, USA. 4. Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. 5. Department of Urology, Fundacio Puigvert, Barcelona, Spain. 6. Department of Urology, Azienda Unita Sanitaria Locale Modena, Modena, Italy. 7. Department of Urologic Sciences, The University of British Columbia, Vancouver, Canada. 8. Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. Electronic address: stbwilli@utmb.edu.
Abstract
CONTEXT: Current guidelines remain ill-defined regarding the optimal intravesical chemotherapy type and regimen for the treatment of non-muscle-invasive bladder cancer (NMIBC). Although maintenance therapy is a standard part of bacillus Calmette-Guerin (BCG) therapy, its role in the context of chemotherapy remains debatable. OBJECTIVE: We reviewed the literature regarding the utilization of intravesical maintenance chemotherapy in the treatment of NMIBC to determine its impact on recurrence, progression, and survival. EVIDENCE ACQUISITION: A systematic search was conducted using Ovid and Medline according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2018 reporting on the utilization of maintenance intravesical chemotherapy. Only randomized controlled trials (RCTs) that included a comparison between an induction regimen and an induction plus maintenance regimen were included. EVIDENCE SYNTHESIS: Sixteen RCTs were included in the final analysis. The most commonly studied intravesical chemotherapy agents used in maintenance regimens were epirubicin, doxorubicin, and mitomycin C. Several maintenance schedules were utilized, some as short as 3mo and others as long as 3 yr, while the most common maintenance regimen utilized was monthly instillation for 1 yr. Of the 16 trials, 13 reported no significant improvement in recurrence for patients receiving maintenance compared with no maintenance, and none of the trials demonstrated a significant impact on progression or survival. CONCLUSIONS: Intermediate length maintenance regimens lasting 7-12mo were the most common maintenance regimens utilized. There was considerable heterogeneity between trial design and duration of follow-up, making direct comparisons for recurrence, progression, and survival outcomes between trials challenging. Although maintenance intravesical chemotherapy is suggested as a treatment option for patients with NMIBC by some guidelines, the majority of evidence suggested that it provided no significant advantage over induction therapy alone with respect to recurrence, progression, or survival. PATIENT SUMMARY: In this review, we reviewed prior clinical trials to determine whether prolonged intravesical chemotherapy ("maintenance therapy") improved the rates of recurrence, progression, and survival. Where differences were found in favor of maintenance therapy, there was no statistical significance demonstrated, possibly due to the underpowered nature of the study design. While there was no consensus on an optimal agent or maintenance schedule, we found no evidence to suggest that maintenance therapy would improve recurrence, progression, or survival.
CONTEXT: Current guidelines remain ill-defined regarding the optimal intravesical chemotherapy type and regimen for the treatment of non-muscle-invasive bladder cancer (NMIBC). Although maintenance therapy is a standard part of bacillus Calmette-Guerin (BCG) therapy, its role in the context of chemotherapy remains debatable. OBJECTIVE: We reviewed the literature regarding the utilization of intravesical maintenance chemotherapy in the treatment of NMIBC to determine its impact on recurrence, progression, and survival. EVIDENCE ACQUISITION: A systematic search was conducted using Ovid and Medline according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2018 reporting on the utilization of maintenance intravesical chemotherapy. Only randomized controlled trials (RCTs) that included a comparison between an induction regimen and an induction plus maintenance regimen were included. EVIDENCE SYNTHESIS: Sixteen RCTs were included in the final analysis. The most commonly studied intravesical chemotherapy agents used in maintenance regimens were epirubicin, doxorubicin, and mitomycin C. Several maintenance schedules were utilized, some as short as 3mo and others as long as 3 yr, while the most common maintenance regimen utilized was monthly instillation for 1 yr. Of the 16 trials, 13 reported no significant improvement in recurrence for patients receiving maintenance compared with no maintenance, and none of the trials demonstrated a significant impact on progression or survival. CONCLUSIONS: Intermediate length maintenance regimens lasting 7-12mo were the most common maintenance regimens utilized. There was considerable heterogeneity between trial design and duration of follow-up, making direct comparisons for recurrence, progression, and survival outcomes between trials challenging. Although maintenance intravesical chemotherapy is suggested as a treatment option for patients with NMIBC by some guidelines, the majority of evidence suggested that it provided no significant advantage over induction therapy alone with respect to recurrence, progression, or survival. PATIENT SUMMARY: In this review, we reviewed prior clinical trials to determine whether prolonged intravesical chemotherapy ("maintenance therapy") improved the rates of recurrence, progression, and survival. Where differences were found in favor of maintenance therapy, there was no statistical significance demonstrated, possibly due to the underpowered nature of the study design. While there was no consensus on an optimal agent or maintenance schedule, we found no evidence to suggest that maintenance therapy would improve recurrence, progression, or survival.
Authors: D A Tolley; M K Parmar; K M Grigor; G Lallemand; L L Benyon; J Fellows; L S Freedman; K M Grigor; R R Hall; T B Hargreave; K Munson; D W Newling; B Richards; M R Robinson; M B Rose; P H Smith; J L Williams; P Whelan Journal: J Urol Date: 1996-04 Impact factor: 7.450
Authors: K Okamura; T Kinukawa; Y Tsumura; T Otani; H Itoh; H Kobayashi; O Matsuura; M Kobayashi; T Fukatsu; S Ohshima Journal: Eur Urol Date: 1998 Impact factor: 20.096
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Samantha Cambier; Richard J Sylvester; Laurence Collette; Paolo Gontero; Maurizio A Brausi; George van Andel; Wim J Kirkels; Fernando Calais Da Silva; Willem Oosterlinck; Stephen Prescott; Ziya Kirkali; Philip H Powell; Theo M de Reijke; Levent Turkeri; Sandra Collette; Jorg Oddens Journal: Eur Urol Date: 2015-07-23 Impact factor: 20.096
Authors: Kees Hendricksen; Wim P J Witjes; Jan G Idema; Jan J M Kums; Oncko B van Vierssen Trip; Marcel J F M de Bruin; Henk Vergunst; Christien T M Caris; Maria H D Janzing-Pastors; J Alfred Witjes Journal: Eur Urol Date: 2007-12-27 Impact factor: 20.096
Authors: Sam S Chang; Stephen A Boorjian; Roger Chou; Peter E Clark; Siamak Daneshmand; Badrinath R Konety; Raj Pruthi; Diane Z Quale; Chad R Ritch; John D Seigne; Eila Curlee Skinner; Norm D Smith; James M McKiernan Journal: J Urol Date: 2016-06-16 Impact factor: 7.450
Authors: Bimal Bhindi; Ronald Kool; Girish S Kulkarni; D Robert Siemens; Armen G Aprikian; Rodney H Breau; Fadi Brimo; Adrian Fairey; Christopher French; Nawar Hanna; Jonathan I Izawa; Louis Lacombe; Victor McPherson; Ricardo A Rendon; Bobby Shayegan; Alan I So; Alexandre R Zlotta; Peter C Black; Wassim Kassouf Journal: Can Urol Assoc J Date: 2021-08 Impact factor: 1.862